Darovasertib

Generic Name: Darovasertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃F_₃N_₈O

CAS Number: 1874276-76-2

Unique Ingredient Identifier: E0YF0M8O09

Background: IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences appoints Stu Dorman as Chief Commercial Officer, leveraging his 20+ years of oncology experience and successful launches of Trodelvy and Opdivo.

dcf.fm

2 months ago

IDEAYA Biosciences, Inc. (IDYA) BCG Matrix Analysis

IDEAYA Biosciences, Inc. (IDYA) is a precision medicine oncology firm with a $1.2 billion cash reserve and a strong pipeline, including darovasertib in Phase 2/3 trials. Despite significant collaborations and financial backing, it faces a $492.5 million deficit and relies on external financing. Its future hinges on clinical trial success and regulatory approvals.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy